AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MAYNE PHARMA GROUP LTD

2.540

+0.0200.79%

Volume:119.71K

Turnover:303.86K

Market Cap:208.00M

PE:12.24

High:2.590

Open:2.550

Low:2.490

Close:2.520

52wk High:6.500

52wk Low:2.040

Shares:81.89M

Float Shares:67.00M

Volume Ratio:1.03

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.208

EPS(LYR):0.208

ROE:8.20%

ROA:-1.73%

PB:0.53

PE(LYR):12.24

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-0.09%

Capital Flow

Inflow:

Outflow:

News

Mayne Pharma Group Receives US FDA Confirmation on Fulfillment of Post-Marketing Requirement for Vaginal Inserts

MT Newswires Live

Mayne Pharma Group Ltd - Fulfilment of Imvexxy Post-Marketing Study Requirements

THOMSON REUTERS

3 Australian Biotech Stocks With At Least 64% Fair Value Upside

Simply Wall St.

3 Australian Biotech Stocks With Up To 77% Fair Value Upside

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketd.com/stock/MYX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":2.54,"timestamp":1791868320000,"preClose":2.52,"halted":0,"volume":119710,"delay":0,"changeRate":0.007936507936507943,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81890887,"eps":0.207588,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"10-13 16:12:00 AEDT","open":2.55,"high":2.59,"low":2.49,"amount":303858,"amplitude":0.039683,"askPrice":2.6,"askSize":7764,"bidPrice":2.49,"bidSize":9689,"shortable":3,"etf":0,"ttmEps":0.207588,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.52,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":1.026139,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":2.52,"auctionPrice":2.54,"auctionVolume":2922,"auction":3,"marketStatus":"盘后竞价","timestamp":1791868208980}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-1.73%","roe":"8.20%","lyrEps":0.207588,"volumeRatio":1.026139,"shares":81890887,"dividePrice":0,"high":2.59,"amplitude":0.039683,"preClose":2.52,"low":2.49,"week52Low":2.04,"pbRate":"0.53","psRate":"0.54","week52High":6.5,"institutionHeld":0,"latestPrice":2.54,"committee":0.110296,"eps":0.207588,"divideRate":0,"volume":119710,"delay":0,"ttmEps":0.207588,"open":2.55,"prevYearClose":3.11,"prevWeekClose":2.66,"prevMonthClose":2.92,"prevQuarterClose":2.92,"fiveDayClose":2.83,"twentyDayClose":3.03,"sixtyDayClose":2.75,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674886132","title":"Mayne Pharma Group Receives US FDA Confirmation on Fulfillment of Post-Marketing Requirement for Vaginal Inserts","url":"https://stock-news.laohu8.com/highlight/detail?id=2674886132","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674886132?lang=en_us&edition=fundamental","pubTime":"2026-10-09 08:05","pubTimestamp":1791504310,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group  received a letter from the US Food and Drug Administration  confirming the company's fulfillment of its post-marketing requirement safety study for IMVEXXY vaginal inserts, according to a Friday filing with the Australian bourse.IMVEXXY is approved by the FDA for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause, the filing said.The study showed that there's no link between very-low-dose vaginal estrogen products and endometrial cancer risk in postmenopausal women, per the filing.Shares fell 2% in morning trade Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYX.AU","LABU","BK7508","BK7096","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674885364","title":"Mayne Pharma Group Ltd - Fulfilment of Imvexxy Post-Marketing Study Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674885364?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:41","pubTimestamp":1791499283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U1D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011506","title":"3 Australian Biotech Stocks With At Least 64% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011506","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011506?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:48","pubTimestamp":1791373688,"startTime":"0","endTime":"0","summary":"IMF warnings about high public debt and the risks around rapid AI investment have pushed many investors to look for sectors where real science backs the story. Australian biotech stocks fit that brief, with businesses built around research pipelines rather than hype. For investors willing to handle higher risk, this corner of the market can be compelling. This article highlights three stocks from our biotech screen that may warrant closer examination.\nThe three biotech stocks below are only a...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-at-least-64-fair-value-upsi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-at-least-64-fair-value-upsi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GEAR.AU","NVIB","XBIX","VAS.AU","BBOZ.AU","QFN.AU","STW.AU","VLS.AU","XJO.AU","BK7508","AIPO","VAP.AU","XAO.AU","XKO.AU","BK7096","GIVE.AU","BEAR.AU","EIGA.AU","IMLC.AU","MYX.AU","CUV.AU","SLF.AU","BK4588","BK4581","E200.AU","OZR.AU","XBI","IIGF.AU","BK7067","IOZ.AU","OZF.AU","QRE.AU","ZYAU.AU","IISV.AU","DACE.AU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672738443","title":"3 Australian Biotech Stocks With Up To 77% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2672738443","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672738443?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:20","pubTimestamp":1790763656,"startTime":"0","endTime":"0","summary":"Australia’s inflation rate sitting at 4% and interest rates at a 15 year high of 4.6% are squeezing many growth stories. Yet that pressure also pushes investors toward companies with solid balance sheets and clear funding runways. That matters for Australian biotechnology stocks, where capital access can make or break a breakthrough. This article highlights three listed biotech opportunities screened for financial resilience and reasonable value.\nThe three biotech stocks covered below are a...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-up-to-77-fair-value-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GEAR.AU","ZYAU.AU","VLS.AU","BK7067","OZF.AU","IIGF.AU","VAS.AU","QRE.AU","XJO.AU","IMLC.AU","GIVE.AU","BK7096","BK7508","STW.AU","DACE.AU","BK4581","XBI","OZR.AU","XAO.AU","MYX.AU","XKO.AU","NVIB","VAP.AU","EIGA.AU","SLF.AU","BEAR.AU","E200.AU","BK4588","BK4585","IOZ.AU","CUV.AU","XBIX","BBOZ.AU","QFN.AU","IISV.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":13,"pageCount":1,"totalSize":51,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MYX.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":-0.000924}]}}